- ￥4300
- 齐源
- 689902
- 国产/进口
- 2025年07月15日
- WB, KO/KD-WB
- 小鼠
- 人
6 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
c-Met
- 级别：
c-Met Antibody
- 目录编号：
c-Met Antibody
- 克隆性：
单克隆
- 抗原来源：
小鼠
- 保质期：
c-Met Antibody
- 抗体英文名：
Purified anti-c-Met Antibody
- 抗体名：
c-Met Antibody
- 标记物：
c-Met Antibody
- 宿主：
小鼠
- 适应物种：
人
- 免疫原：
c-Met Antibody
- 亚型：
c-Met Antibody
- 形态：
c-Met Antibody
- 应用范围：
WB, KO/KD-WB
- 保存条件：
2-8℃
- 浓度：
0.5 mg/ml
- 规格：
100 µg
Purified anti-c-Met Antibody详细如下：
Description ：The Mesenchymal Epithelial Transition (MET) receptor belongs to a family of Receptor tyrosinekinases (RTKs). The MET proto-oncogene is located on chromosome 7q21–31 and encodesthe receptor tyrosine kinase C-Met. It is a 190 kD glycoprotein heterodimer made up of anextracellular α-chain which is linked by a disulphide bond to a transmembrane β-chain. c-Met isinitially synthesised as a 170 kD single polypeptide as precursor that is proteolytically cleavedto form the α-chain and the β-chain. TPR-MET oncogenic fusion protein from humanosteosarcoma tumor cells was first discovered in 1984. c-Met is a hepatocyte growth factor(HGF) receptor. The initiation of MET signaling begins with the binding of HGF to the METreceptor at cell membrane that causes C-Met dimerization. Subsequent activation is through aprocess of trans-phosphorylation of the two tyrosine residues in the catalytical regions Y1234and Y1235, followed by trans-phosphorylation of two docking tyrosines (Y1349 and Y1356). Itenables MET to bind to multiple substrates and activate a variety of signaling pathways, suchas MAPK, PI3K-AKT cascades, STAT and NF-κB signaling pathways. This is responsible fordriving proliferation, cell survival, migration and invasiveness. c-Met is overexpressed indifferent human tumors, such as thyroid, gastric, pancreatic, breast, cervical and prostatecancers. Increasing evidence indicated that MET may be a common mechanism of resistanceto anticancer treatment such as approved EGFR and VEGFR inhibitors, anti-HER2 therapiesand a BRAF inhibitor. Hence, the HGF-MET axis has been targeted in solid tumors toovercome the drug resistance.
Verified Reactivity ：Human
Antibody Type ：Monoclonal
Host Species ：Mouse
Immunogen ：Bacterially expressed human c-Met alpha chain.
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography.
Concentration ：0.5 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C.
Application ：WB - Quality tested、KO/KD-WB - Verified
Recommended Usage ：Each lot of this antibody is quality control tested by Western blotting. For Western blotting, thesuggested use of this reagent is 0.5 - 2.5 µg per ml. It is recommended that the reagent be titratedfor optimal performance for each application.
Description ：The Mesenchymal Epithelial Transition (MET) receptor belongs to a family of Receptor tyrosinekinases (RTKs). The MET proto-oncogene is located on chromosome 7q21–31 and encodesthe receptor tyrosine kinase C-Met. It is a 190 kD glycoprotein heterodimer made up of anextracellular α-chain which is linked by a disulphide bond to a transmembrane β-chain. c-Met isinitially synthesised as a 170 kD single polypeptide as precursor that is proteolytically cleavedto form the α-chain and the β-chain. TPR-MET oncogenic fusion protein from humanosteosarcoma tumor cells was first discovered in 1984. c-Met is a hepatocyte growth factor(HGF) receptor. The initiation of MET signaling begins with the binding of HGF to the METreceptor at cell membrane that causes C-Met dimerization. Subsequent activation is through aprocess of trans-phosphorylation of the two tyrosine residues in the catalytical regions Y1234and Y1235, followed by trans-phosphorylation of two docking tyrosines (Y1349 and Y1356). Itenables MET to bind to multiple substrates and activate a variety of signaling pathways, suchas MAPK, PI3K-AKT cascades, STAT and NF-κB signaling pathways. This is responsible fordriving proliferation, cell survival, migration and invasiveness. c-Met is overexpressed indifferent human tumors, such as thyroid, gastric, pancreatic, breast, cervical and prostatecancers. Increasing evidence indicated that MET may be a common mechanism of resistanceto anticancer treatment such as approved EGFR and VEGFR inhibitors, anti-HER2 therapiesand a BRAF inhibitor. Hence, the HGF-MET axis has been targeted in solid tumors toovercome the drug resistance.
Verified Reactivity ：Human
Antibody Type ：Monoclonal
Host Species ：Mouse
Immunogen ：Bacterially expressed human c-Met alpha chain.
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography.
Concentration ：0.5 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C.
Application ：WB - Quality tested、KO/KD-WB - Verified
Recommended Usage ：Each lot of this antibody is quality control tested by Western blotting. For Western blotting, thesuggested use of this reagent is 0.5 - 2.5 µg per ml. It is recommended that the reagent be titratedfor optimal performance for each application.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
Purified 抗 c-Met 抗体
￥4300
